Interview Summary	Application No. 11/579,462	Applicant(s) BECKER-KOJIC, ZORICA
	Examiner Thaian N. Ton	Art Unit 1632

All participants (applicant, applicant's representative, PTO personnel):

(1) *Thaian N. Ton*. (3)_____.

(2) *Zorica Becker-Kojic*. (4)_____.

Date of Interview: *22 July 2010*.

Type: a)☒ Telephonic b)☐ Video Conference
c)☐ Personal [copy given to: 1)☐ applicant 2)☐ applicant's representative]

Exhibit shown or demonstration conducted: d)☐ Yes e)☒ No.
If Yes, brief description: _____.

Claim(s) discussed: *Of Record*.

Identification of prior art discussed: *Of record*.

Agreement with respect to the claims f)☐ was reached. g)☒ was not reached. h)☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: *Discussed outstanding rejections of record and Dr. Becker-Kojic's proposed response.*.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

/Thaian N. Ton/
Primary Examiner, Art Unit 1632

1-2

Examiner's suggestion to overcome this problem by applaying the request for continuation, while patent is pending is highly appreciated.

Concerning hematopoietic stem cells (HSCs) I have presented the argumentation that the scpecification while enabling for maintenance and expansion of HSCs also refer to generation of HSCs. The argumentation was as follows: As shown in the scpecification, the sorted CD34 positive cells expressing CD38 marker represent a hematopoietic progenitor cell population, with round non-polar morhology. After incubation with ACA specific antibody, these cells turned completely into cells with spindle morphology giving rise to generation of assymmetrically dividing cells (CD34+/CD38-) e.g. hematopoietic stem cells. The generation of the assymmetrically dividing cell (CD34+/CD38-) with polar spindle morphology, starting from progenitor cells (CD34+/CD38-)with round non-polar morphology, is a result of action of ACA. Crosslinking of ACA with specific antibody to ACA, changes the previous distribution of rafts, leading finally to their accumulation at one side of the cell membrane (spindle) allowing for concentration of the receptors for interaction with the ligands. This reaction is crucial for the mechanism of action of ACA as well as for the self –renewal for stem cell and explained why I think that the method described in the specification refres to generation, expansion and maintenace,

Regards,

Zorica Becker-Kojic

Dr. Zorica Becker-Kojic

2-2

RECEIVED
CENTRAL FAX CENTER

SEP 0 7 2010

Patent Application No.: 10/579,462

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:
Zorica A. Becker-Kojić Ph. D.
Johann-Casimir-Weg 4
69181 Leimen

Phone: +49 6224 9771012
e-mail: becker-kojic@gmx.de

Examiner: **Thaian N. Ton**
Art Unit: **1632**

Application No.: 11/579,462

Filed: November 3, 2006

Leimen, September 2, 2010

For: USE OF THE ACA GLYCOPROTEIN FOR OBTAINING / MAINTAINING PLURIPOTENT NON-EMBRYONIC STEM CELLS

Summary of record of Inerview held on 22 July 2010

Commisioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Signature and Date
Zorica Becker Kojić, Sept. 2. 2010

Dear Sir:

This is in response to the substance of telephonic interview held on 22 July 2010 between applicant Dr. Becker-Kojic and examiner Dr. Thaian N. Ton. Discussed are the outstanding rejections of record and Dr. Becker-Kojic's proposed response.
I brief, while the objections stated by Examiner concerning the activators other than using ACA-specific antibody, or GPI-anchored glycoprotein ACA are removed from the claims, and the argumentation regarding generation of pluripotent stem cells starting with hematopoietic progenitor cells (CD34+/CD38+) which could be probative for the argumentation that the method described in the specification enable for generation of pluripotent stem cells as well, cannot be presented to the Examiner because the work is under review in Nature and displaying these data would compromise the process of accepting it for publication, a request for continuation will be filed . The